Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to chief executive officer from head of Research & Development. Coughlin has been an Avacta board member since March 2022 and head of R&D since this past February. She replaces Alastair Smith, who steps down on Tuesday after 19 years as CEO. Coughlin was CEO of Cytolmmune Therapeutics, which develops cell therapy solutions from a facility in Puerto Rico. She also has worked at Pfizer Inc and Novartis AG.
Current stock price: 44.40 pence
12-month change: down 63%
By Tom Waite, Alliance News editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Avacta Group (AVCT)